• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胸部放疗后接受卡巴他赛治疗的去势抵抗性前列腺癌患者的间质性肺炎:病例报告。

Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report.

机构信息

Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-0016, Japan.

出版信息

BMC Cancer. 2019 Jul 22;19(1):720. doi: 10.1186/s12885-019-5942-4.

DOI:10.1186/s12885-019-5942-4
PMID:31331293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6647250/
Abstract

BACKGROUND

Interstitial pneumonitis is a rare reaction in a previously irradiated area of pulmonary or thoracic lesion after treatment with anticancer drugs such as taxanes.

CASE PRESENTATION

A 66-year-old man presented with a fever and dyspnea after treatment with cabazitaxel for castration-resistant prostate cancer. He was treated with an intravenous broad-spectrum antimicrobial agent, however he complained of dyspnea and had a pulse oximetric saturation of 80% while breathing room air. The patients had been treated for bone metastases with 37.5 Gy to the thoracic spine (Th 7) as a local radiotherapy. Radiological images showed pulmonary interstitial opacities in the irradiated field of the both lungs. The steroid pulse therapy was started. The patient's dyspnea disappeared and the interstitial opacities had also improved.

CONCLUSIONS

This report is a case of interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy.

摘要

背景

间质性肺炎是在接受紫杉醇类抗癌药物治疗后,肺部或胸部病变的先前照射区域出现的罕见反应。

病例介绍

一名 66 岁男性在接受卡巴他赛治疗去势抵抗性前列腺癌后出现发热和呼吸困难。他接受了静脉广谱抗菌药物治疗,但他主诉呼吸困难,在呼吸室内空气时脉搏血氧饱和度为 80%。患者曾因骨转移接受过局部放疗,胸 7 椎体 37.5Gy 照射。影像学图像显示双肺照射野有肺间质混浊。开始使用类固醇脉冲治疗。患者的呼吸困难消失,间质混浊也有所改善。

结论

本报告是一例接受卡巴他赛治疗的去势抵抗性前列腺癌患者在胸部放疗后发生间质性肺炎的病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d7/6647250/01d85fbd192b/12885_2019_5942_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d7/6647250/39cb477541a4/12885_2019_5942_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d7/6647250/01d85fbd192b/12885_2019_5942_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d7/6647250/39cb477541a4/12885_2019_5942_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d7/6647250/01d85fbd192b/12885_2019_5942_Fig2_HTML.jpg

相似文献

1
Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report.胸部放疗后接受卡巴他赛治疗的去势抵抗性前列腺癌患者的间质性肺炎:病例报告。
BMC Cancer. 2019 Jul 22;19(1):720. doi: 10.1186/s12885-019-5942-4.
2
Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.液体活检早期检测转移后,在一名接受 cabazitaxel 早期治疗的去势抵抗性前列腺癌多发肺转移患者中的完全缓解:病例报告。
BMC Cancer. 2019 Jun 11;19(1):562. doi: 10.1186/s12885-019-5782-2.
3
The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.卡巴他赛治疗多西紫杉醇耐药前列腺癌的疗效和毒性与日本患者的初始剂量相关。
BMC Cancer. 2019 Feb 15;19(1):156. doi: 10.1186/s12885-019-5342-9.
4
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.卡巴他赛联合考比司他和泼尼松与单独卡巴他赛和泼尼松治疗多西他赛治疗后转移性去势抵抗性前列腺癌患者(AFFINITY):一项随机、开放标签、国际、3 期临床试验。
Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9.
5
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.卡巴他赛的真实世界安全性:意大利转移性去势抵抗性前列腺癌早期准入项目
Future Oncol. 2014 May;10(6):975-83. doi: 10.2217/fon.13.256. Epub 2013 Dec 3.
6
Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.转移性去势抵抗性前列腺癌:卡巴他赛带来的治疗格局变化。
Anticancer Drugs. 2014 Mar;25(3):237-43. doi: 10.1097/CAD.0000000000000045.
7
Severe interstitial pneumonitis associated with the administration of taxanes.与紫杉烷类药物给药相关的严重间质性肺炎。
J Infect Chemother. 2010 Oct;16(5):340-4. doi: 10.1007/s10156-010-0058-4. Epub 2010 Mar 31.
8
Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan.日本使用卡巴他赛治疗的转移性去势抵抗性前列腺癌患者生存不良的危险因素
Anticancer Res. 2019 Oct;39(10):5803-5809. doi: 10.21873/anticanres.13784.
9
Optic atrophy after cabazitaxel treatment in a patient with castration-resistant prostate cancer: a case report.卡巴他赛治疗去势抵抗性前列腺癌患者后发生视神经萎缩:病例报告。
Scott Med J. 2019 May;64(2):71-73. doi: 10.1177/0036933018810653. Epub 2018 Nov 5.
10
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.反驳观点:在有症状的转移性去势抵抗性前列腺癌中,多西他赛和镭-223应首先使用哪一种?镭-223是骨转移为主的有症状转移性去势抵抗性前列腺癌的首选治疗方法。
Clin Adv Hematol Oncol. 2015 May;13(5):293-8.

本文引用的文献

1
Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel.卡巴他赛治疗的日本前列腺癌患者中 3/4 级中性粒细胞减少症的预后意义。
Cancer Sci. 2018 May;109(5):1570-1575. doi: 10.1111/cas.13556. Epub 2018 Apr 10.
2
Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.卡巴他赛用于前列腺癌治疗时不存在累积毒性。
Medicine (Baltimore). 2016 Jan;95(2):e2299. doi: 10.1097/MD.0000000000002299.
3
Hemorrhagic cystitis in a patient without a past history of radiation therapy who was treated with cabazitaxel for CRPC.
一名既往无放疗史、接受卡巴他赛治疗去势抵抗性前列腺癌(CRPC)的患者发生了出血性膀胱炎。
Ann Oncol. 2015 Nov;26(11):2355-6. doi: 10.1093/annonc/mdv362. Epub 2015 Sep 7.
4
Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer.卡巴他赛用于转移性去势抵抗性前列腺癌的日本 I 期研究。
Int J Clin Oncol. 2015 Oct;20(5):1026-34. doi: 10.1007/s10147-015-0820-9. Epub 2015 Mar 26.
5
New agents for prostate cancer.用于前列腺癌的新药物。
Ann Oncol. 2014 Sep;25(9):1700-1709. doi: 10.1093/annonc/mdu038. Epub 2014 Mar 20.
6
Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer.肺癌放疗后化疗引起的放射性肺 recall 性肺炎。
Radiat Oncol. 2011 Mar 6;6:24. doi: 10.1186/1748-717X-6-24.
7
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者中,泼尼松联合卡巴他赛或米托蒽醌治疗的随机开放标签试验。
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.